Initial trial data have become available regarding an experimental cancer candidate being advanced by Alterome. The therapeutic agent is designed to specifically inhibit KRAS-driven disease processes across several tumor types. Researchers are currently tracking its effects in patients suffering from pancreas, lung, and colon cancers. Continued analysis of these findings will determine the candidate's trajectory toward further clinical development.
Key points
Early clinical findings provide critical initial data regarding the performance of Altero…: Early clinical findings provide critical initial data regarding the performance of Alterome's novel KRAS inhibitor.
The targeted therapeutic intervention addresses three major oncology settings encompassin…: The targeted therapeutic intervention addresses three major oncology settings encompassing pancreas, lung, and colon cancers.
Subsequent updates will rely on how these preliminary findings establish the compound's b…: Subsequent updates will rely on how these preliminary findings establish the compound's broader efficacy and safety.
Sources checked by our analysis pipeline: 1
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today’s newsletter has a bit of everything: peptides, China, Congress, and cancer drugs. Biotech in 2026 is never dull.
Hims and Noom take peptides further into mainstream
Hims & Hers and Noom are getting into the synthetic peptide business, bringing treatments marketed for muscle maintenance, intimacy, and longevity to a much larger audience — often with little evidence to support those uses. Both are already offering compounded drugs and eyeing BPC-157 and TB-500, two of six unapproved peptides covered by a new HHS policy easing enforcement against compounding pharmacies, STAT’s Sarah Todd and Katie Palmer write.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Patients using the weight-loss drug Zepbound often face the unintended physical effect of muscle reduction during their treatment. However, maintaining a consistent resistance workout routine allows these individuals to successfully build physical power despite that tissue loss. This targeted exercise strategy provides an effective way to protect functional capacity while undergoing GLP-1 therapy.
Staff at a mountain lodge acted immediately after a basset hound arrived alone and distressed, prompting an urgent multi-agency wilderness search in sub-freezing conditions. Rescuers mobilized forest rangers, aviation units, and tracking dogs to locate the vulnerable individual before freezing temperatures turned fatal. Thanks to the early alert, search teams successfully retrieved the man from rugged terrain and airlifted him to emergency medical care.
Major global drugmakers have achieved substantial time savings by expanding artificial intelligence applications into core scientific processes rather than limiting them to administrative tasks. At the same time, top pharmaceutical firms are altering their clinical footprints abroad in response to sustained pressure from federal lawmakers. These parallel shifts highlight growing operational transformations across molecular discovery pipelines and international research strategies.